Roivant Sciences Ltd.
ROIV
$20.81
-$0.06-0.29%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.33M | 23.23M | 29.05M | 30.50M | 37.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.33M | 23.23M | 29.05M | 30.50M | 37.05M |
| Cost of Revenue | 601.95M | 579.18M | 545.52M | 506.43M | 466.52M |
| Gross Profit | -581.62M | -555.94M | -516.47M | -475.93M | -429.48M |
| SG&A Expenses | 617.78M | 684.54M | 649.31M | 521.32M | 489.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.22B | 1.26B | 1.19B | 1.03B | 956.47M |
| Operating Income | -1.20B | -1.24B | -1.17B | -997.25M | -919.42M |
| Income Before Tax | -865.87M | -931.21M | -681.59M | -579.27M | 4.81B |
| Income Tax Expenses | 35.40M | 40.86M | 48.17M | -6.92M | 41.01M |
| Earnings from Continuing Operations | -901.27 | -972.07 | -729.76 | -572.35 | 4.77K |
| Earnings from Discontinued Operations | 327.02M | 283.94M | 373.03M | 285.49M | -100.04M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 200.28M | 197.50M | 184.75M | 170.23M | 142.45M |
| Net Income | -373.97M | -490.63M | -171.98M | -116.62M | 4.81B |
| EBIT | -1.20B | -1.24B | -1.17B | -997.25M | -919.42M |
| EBITDA | -1.19B | -1.23B | -1.15B | -977.55M | -899.15M |
| EPS Basic | -0.55 | -0.70 | -0.24 | -0.14 | 5.99 |
| Normalized Basic EPS | -0.63 | -0.61 | -0.53 | -0.38 | -0.36 |
| EPS Diluted | -0.56 | -0.70 | -0.24 | -0.14 | 5.66 |
| Normalized Diluted EPS | -0.63 | -0.61 | -0.52 | -0.38 | -0.36 |
| Average Basic Shares Outstanding | 2.79B | 2.85B | 2.90B | 3.00B | 3.07B |
| Average Diluted Shares Outstanding | 2.79B | 2.85B | 2.95B | 3.04B | 3.16B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |